capecitabine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- Thymidylate synthase inhibitor
pharma · Breast Cancer · Lumbosacral Radicular Pain · SMNR
Semnur Pharmaceuticals
Semnur Pharmaceuticals drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Palo Alto, USA HQ
2013 Founded
9 Employees
Public company Type
SMNR · NYSE Ticker
Company details
- Status
- Public
- HQ
- Palo Alto, USA
- Founded
- 2013
- Employees
- 9
- Programs
- 2
- Drugs
- 2
- Patents
- 8
Semnur Pharmaceuticals pipeline
Portfolio lens on 2 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Semnur Pharmaceuticals drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor